16:05 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Ark's ziresovir stops worsening of RSV symptoms in Phase II

Ark Biosciences Inc. (Shanghai, China) reported data from the Phase II VICTOR trial in hospitalized infants with respiratory syncytial virus (RSV) infection showing that no infant who received a single dose of oral ziresovir (AK0529)...
20:48 , Nov 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Cell culture, mouse and rat studies identified an RSV F protein inhibitor that could help treat RSV infection. Optimization and testing in HeLa cell-based assays of a previously reported quinoline-based...
18:38 , Sep 7, 2018 |  BC Week In Review  |  Company News

Shanghai-based Ark licenses Roche IPF therapy

Ark Biosciences Inc. (Shanghai, China) gained exclusive, worldwide rights from Roche (SIX:ROG; OTCQX:RHHBY) to develop and commercialize AK3280 (GDC3280) to treat idiopathic pulmonary fibrosis. Roche is eligible to receive milestone payments and royalties and will...
04:24 , Sep 3, 2018 |  BC Extra  |  Company News

Shanghai-based Ark licenses Roche IPF therapy

Ark Biosciences Inc. (Shanghai, China) gained exclusive, worldwide rights from Roche (SIX:ROG; OTCQX:RHHBY) to develop and commercialize AK3280 (GDC3280) to treat idiopathic pulmonary fibrosis. Roche is eligible to receive milestone payments and royalties and will...
21:28 , Aug 1, 2018 |  BioCentury  |  Finance

Safety goes (Re)Viral

The clean safety profile and clinical efficacy of ReViral Ltd.’s respiratory syncytial virus therapy prompted Novo Ventures to co-lead the biotech’s $55 million series B round with fellow new investor New Leaf Venture Partners. The...
21:27 , Nov 10, 2017 |  BC Week In Review  |  Company News

Ark, Calibr in COPD deal

Ark Biosciences Inc. (Shanghai, China) partnered with the California Institute for Biomedical Research (La Jolla, Calif.) to develop “first-in-class” therapies for chronic obstructive pulmonary disease and related lung diseases. Ark said it will be responsible...
00:47 , Nov 8, 2017 |  BC Extra  |  Company News

Ark, Calibr in COPD deal

Ark Biosciences Inc. (Shanghai, China) partnered with the California Institute for Biomedical Research (La Jolla, Calif.) to develop “first-in-class” therapies for chronic obstructive pulmonary disease and related lung diseases. Ark said it will be responsible...
21:47 , Feb 10, 2017 |  BC Week In Review  |  Financial News

Ark Biosciences completes venture financing

On Feb. 5, antiviral company Ark Biosciences Inc. (Shanghai, China) raised an undisclosed amount in a series A round led by Bioventure Investment Management. Ark Biosciences Inc. , Shanghai, China ...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

AK0529: Phase II started

Ark began the double-blind, placebo-controlled, international Phase II VICTOR trial to evaluate single and multiple doses of oral AK0529 in about 80 hospitalized infants with RSV infection. Ark has exclusive, worldwide rights to develop and...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

AK0529: Phase I data

Top-line data from a double-blind, placebo-controlled, Australian Phase I trial in 64 healthy volunteers showed that single and multiple ascending doses of up to 1,200 mg oral AK0529 were well tolerated with no serious adverse...